Diloxanide furoate: Difference between revisions
Jump to navigation
Jump to search
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{CMG}} | |||
==Overview== | |||
Diloxanide furoate is an anti-protozoal drug used in the treatment of [[Entamoeba histolytica]] and some other protozoal infections. | |||
==Category== | |||
== | Antiparasitic | ||
==US Brand Names== | |||
ENTAMIDE, FUMARIDE (not available in the U.S.) | |||
==Mechanism of Action== | |||
==Safety and Effectiveness== | |||
A 13-year study conducted by the United States [[Center for Disease Control]] between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of ''[[Entamoeba histolytica]].'' <ref name="pmid1520794">{{cite journal |author=McAuley JB, Herwaldt BL, Stokes SL, ''et al'' |title=Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States |journal=Clin. Infect. Dis. |volume=15 |issue=3 |pages=464–8 |year=1992 |pmid=1520794 |doi=}}</ref> | |||
==Availability== | |||
A [[CDC]] study authorized the use of this drug in the treatment of 4,371 cases of ''[[Entamoeba histolytica]]'' from 1977 to 1990. <ref name="pmid1520794" /> | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] |
Revision as of 02:29, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diloxanide furoate is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections.
Category
Antiparasitic
US Brand Names
ENTAMIDE, FUMARIDE (not available in the U.S.)
Mechanism of Action
Safety and Effectiveness
A 13-year study conducted by the United States Center for Disease Control between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of Entamoeba histolytica. [1]
Availability
A CDC study authorized the use of this drug in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990. [1]